{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:42Z","timestamp":1786987542133,"version":"build-2736575974"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.critrevonc.2016.07.005","type":"journal-article","created":{"date-parts":[[2016,7,17]],"date-time":"2016-07-17T01:29:33Z","timestamp":1468718973000},"page":"14-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide"],"prefix":"10.1016","volume":"106","author":[{"given":"Giulia","family":"Baciarello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2016.07.005_bib0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/jcb.20811","article-title":"Androgen receptor action in hormone-dependent and recurrent prostate cancer","volume":"99","author":"Agoulnik","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.eururo.2014.04.015","article-title":"Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies","volume":"68","author":"Al Nakouzi","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0015","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andre","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0020","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2016.07.005_bib0025","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdu438.23","article-title":"AR-V7 splice variant and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC): overall survival results","volume":"25","author":"Antonarakis","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0030","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","article-title":"Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Antonarakis","year":"2015","journal-title":"JAMA Oncol."},{"issue":"suppl","key":"10.1016\/j.critrevonc.2016.07.005_bib0035","article-title":"AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): expanded analysis of the Johns Hopkins cohort","volume":"34","author":"Antonarakis","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0040","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0045","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s10637-014-0091-8","article-title":"A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naive castration-resistant prostate cancer","volume":"32","author":"Azad","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2014.06.045","article-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","volume":"67","author":"Azad","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0055","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0060","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/cncr.28518","article-title":"Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment","volume":"120","author":"Badrising","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0065","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0070","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"15 Suppl","key":"10.1016\/j.critrevonc.2016.07.005_bib0075","doi-asserted-by":"crossref","first-page":"Abstr 5036","DOI":"10.1200\/jco.2015.33.15_suppl.5036","article-title":"Enzalutamide (ENZA) in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer (mCRPC): final analysis of the phase 3 PREVAIL study","volume":"33","author":"Beer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2013.08.020","article-title":"Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone","volume":"50","author":"Bianchini","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2016.07.005_bib0085","first-page":"S699","article-title":"Enzalutamide (ENZA) in heavily pretreated patients with bone metastatic castration resistant prostate cancer (mCRPC) resistant to androgen biosynthesis inhibitor (ABI) treatment-the Hellenic experience of the Name Patient Access Program (NPAP)","volume":"49","author":"Bournakis","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0090","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2014.07.028","article-title":"Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis","volume":"68","author":"Brasso","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eururo.2014.10.014","article-title":"Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an italian multicentre study","volume":"68","author":"Caffo","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/annonc\/mdu510","article-title":"Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial","volume":"26","author":"Cella","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.coph.2008.07.005","article-title":"Targeting the androgen receptor pathway in prostate cancer","volume":"8","author":"Chen","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0110","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/pcan.2014.53","article-title":"Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and\/or docetaxel","volume":"18","author":"Cheng","year":"2015","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ctrv.2015.12.003","article-title":"AR-V7 and prostate cancer: the watershed for treatment selection","volume":"43","author":"Ciccarese","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0120","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0125","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/sj.bjc.6690684","article-title":"Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system","volume":"81","author":"Culig","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0130","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","article-title":"Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer","volume":"71","author":"Darshan","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0135","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0140","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2016.02.010","article-title":"Practical guidance on the role of corticosteroids in the treatment of metastatic castration-resistant prostate cancer","author":"De Santis","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0150","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/ERC-11-0141","article-title":"Alternatively spliced androgen receptor variants","volume":"18","author":"Dehm","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0155","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1200\/JCO.2010.33.7675","article-title":"Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone","volume":"30","author":"Efstathiou","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2016.07.005_bib0160","first-page":"Abstr 2854","article-title":"The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC)","volume":"49","author":"Efstathiou","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0165","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.05.005","article-title":"Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer","volume":"67","author":"Efstathiou","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0170","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0175","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","article-title":"The development of androgen-independent prostate cancer","volume":"1","author":"Feldman","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0180","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0185","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","article-title":"Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.yfrne.2007.10.005","article-title":"Non-genomic actions of androgens","volume":"29","author":"Foradori","year":"2008","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2016.03.070","article-title":"Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors","volume":"61","author":"Fuerea","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"Suppl 7","key":"10.1016\/j.critrevonc.2016.07.005_bib0200","doi-asserted-by":"crossref","first-page":"Abstr 227","DOI":"10.1200\/jco.2015.33.7_suppl.227","article-title":"Previous enzalutamide therapy and response to subsequent taxane therapy in metastatic castration-resistant prostate cancer","volume":"33","author":"Gizzi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0205","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdv542","article-title":"Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL","volume":"27","author":"Graff","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0210","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II. Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur. Urol."},{"issue":"Suppl 4","key":"10.1016\/j.critrevonc.2016.07.005_bib0215","first-page":"iv255","article-title":"Response rates and outcomes with enzalutamide for patients with metastatic castration resistant prostate cancer and visceral disease in the PREVAIL trial","volume":"25","author":"Higano","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0220","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2015.01.026","article-title":"Long-term safety and antitumor activity in the phase 1\u20132 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer","volume":"68","author":"Higano","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0225","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Hu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0230","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0235","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12672-014-0173-2","article-title":"Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer","volume":"5","author":"Isikbay","year":"2014","journal-title":"Horm. Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0240","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0245","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0022-5347(01)64039-4","article-title":"High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy","volume":"159","author":"Joyce","year":"1998","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0250","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0255","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.eururo.2014.09.049","article-title":"Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level","volume":"67","author":"Karantanos","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0260","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876\u2009L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0265","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0090-4295(01)01010-X","article-title":"Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235)","volume":"58","author":"Kucuk","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0270","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdt136","article-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","volume":"24","author":"Loriot","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0275","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(15)70113-0","volume":"16","author":"Loriot","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0280","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0285","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","article-title":"Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth","volume":"19","author":"Mulholland","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0290","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrurol.2015.254","article-title":"Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy","volume":"13","author":"Narayanan","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0295","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology\u2014Prostate Cancer, 2016. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0300","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1158\/1078-0432.CCR-13-1763","article-title":"Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary","volume":"19","author":"Ning","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0305","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","article-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","volume":"24","author":"Noonan","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0310","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0315","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200023050-00003","article-title":"Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance","volume":"23","author":"Paul","year":"2000","journal-title":"Drug Saf."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0320","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","article-title":"Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial","volume":"34","author":"Penson","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0325","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.eururo.2013.11.044","article-title":"Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents","volume":"66","author":"Pezaro","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0330","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0335","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bju.12826","article-title":"Is there an antiandrogen withdrawal syndrome with enzalutamide?","volume":"115","author":"Rodriguez-Vida","year":"2015","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0340","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5489\/cuaj.2526","article-title":"The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)","volume":"9","author":"Saad","year":"2015","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0345","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0350","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1200\/JCO.1997.15.8.2928","article-title":"Bicalutamide for advanced prostate cancer: the natural versus treated history of disease","volume":"15","author":"Scher","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0355","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0360","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0365","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 6","key":"10.1016\/j.critrevonc.2016.07.005_bib0370","doi-asserted-by":"crossref","first-page":"Abstr 6","DOI":"10.1200\/jco.2013.31.6_suppl.6","article-title":"Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor [abstract]","volume":"31","author":"Scher","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0375","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12325-014-0092-1","article-title":"Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer","volume":"31","author":"Schmid","year":"2014","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0380","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.eururo.2013.06.042","article-title":"Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone","volume":"65","author":"Schrader","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0385","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1078-0432.CCR-08-1910","article-title":"Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer","volume":"15","author":"Schwarzenbach","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0390","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0395","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","volume":"17","author":"Shore","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0400","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40618-016-0430-z","article-title":"Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients","volume":"39","author":"Sideris","year":"2016","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0405","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0410","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0415","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","article-title":"Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition","volume":"22","author":"Smith","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0420","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0425","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/pros.22841","article-title":"Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway","volume":"74","author":"Song","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0430","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/0008-5472.CAN-08-3605","article-title":"Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy","volume":"69","author":"Steinkamp","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0435","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/annonc\/mdt571","article-title":"Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial","volume":"25","author":"Sternberg","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0440","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/pros.22844","article-title":"Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone","volume":"74","author":"Suzman","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0445","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0450","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0455","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/21681805.2013.860189","article-title":"Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate","volume":"48","author":"Thomsen","year":"2014","journal-title":"Scand. J. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0460","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ejca.2013.12.017","article-title":"Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer","volume":"50","author":"Thomson","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0465","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","article-title":"Long-term efficacy and safety of enzalutamide monotherapy in hormone-naive prostate cancer: 1- and 2-year open-label follow-up results","volume":"68","author":"Tombal","year":"2015","journal-title":"Eur. Urol."},{"issue":"Suppl. 10","key":"10.1016\/j.critrevonc.2016.07.005_bib0470","doi-asserted-by":"crossref","first-page":"x251","DOI":"10.1093\/annonc\/mds325","article-title":"Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?","volume":"23","author":"Tombal","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0475","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0480","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ejca.2013.09.026","article-title":"Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer","volume":"49","author":"Van Soest","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0485","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2014.11.033","article-title":"Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer","volume":"67","author":"Van Soest","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0490","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0006-291X(05)80067-1","article-title":"A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens","volume":"173","author":"Veldscholte","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0495","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0500","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2016.0494","article-title":"Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer","author":"Wyatt","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0505","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1002\/ijc.29147","article-title":"The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors","volume":"136","author":"Xie","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0510","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cellsig.2016.01.013","article-title":"The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance","volume":"28","author":"Zarif","year":"2016","journal-title":"Cell Signal."},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0515","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clgc.2015.01.004","article-title":"Exploring the clinical benefit of docetaxel or enzalutamide after disease progression during abiraterone acetate and prednisone treatment in men with metastatic castration-resistant prostate cancer","volume":"13","author":"Zhang","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.005_bib0520","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","article-title":"Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer","volume":"70","author":"Zhu","year":"2010","journal-title":"Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T22:14:23Z","timestamp":1600899263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816301615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":104,"alternative-id":["S1040842816301615"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.07.005","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}